| A consensus molecular classification of muscle-invasive bladder cancer A Kamoun, A de Reyniès, Y Allory, G Sjödahl, AG Robertson, R Seiler, ... European urology 77 (4), 420-433, 2020 | 937 | 2020 |
| Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ... European urology 72 (4), 544-554, 2017 | 756 | 2017 |
| Claudin-low bladder tumors are immune infiltrated and actively immune suppressed J Kardos, S Chai, LE Mose, SR Selitsky, B Krishnan, R Saito, MD Iglesia, ... JCI insight 1 (3), 2016 | 215 | 2016 |
| Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy R Saito, CC Smith, T Utsumi, LM Bixby, J Kardos, SE Wobker, KG Stewart, ... Cancer research 78 (14), 3954-3968, 2018 | 100 | 2018 |
| MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma ST Bailey, AM Smith, J Kardos, SE Wobker, HL Wilson, B Krishnan, ... Nature communications 8 (1), 15770, 2017 | 77 | 2017 |
| Intrinsic genomic differences between African American and white patients with clear cell renal cell carcinoma B Krishnan, TL Rose, J Kardos, MI Milowsky, WY Kim JAMA oncology 2 (5), 664-667, 2016 | 57 | 2016 |
| The cancer/testes (CT) antigen HORMAD1 promotes homologous recombinational DNA repair and radioresistance in lung adenocarcinoma cells Y Gao, J Kardos, Y Yang, TY Tamir, E Mutter-Rottmayer, B Weissman, ... Scientific reports 8 (1), 15304, 2018 | 53 | 2018 |
| Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype J Kardos, SE Wobker, ME Woods, ME Nielsen, AB Smith, EM Wallen, ... JCO Precision Oncology 1, 1-12, 2017 | 37 | 2017 |
| Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy TL Rose, DD Chism, AS Alva, AM Deal, SJ Maygarden, YE Whang, ... British Journal of Cancer 119 (7), 801-807, 2018 | 30 | 2018 |
| RNA expression profiling of lymphoepithelioma-like carcinoma of the bladder reveals a basal-like molecular subtype U Manocha, J Kardos, S Selitsky, M Zhou, SM Johnson, C Breslauer, ... The American Journal of Pathology 190 (1), 134-144, 2020 | 16 | 2020 |
| Development and validation of a NanoString BASE47 bladder cancer gene classifier J Kardos, TL Rose, U Manocha, SE Wobker, JS Damrauer, TJ Bivalaqua, ... PLoS One 15 (12), e0243935, 2020 | 10 | 2020 |
| Bladder Cancer Molecular Taxonomy Group A Kamoun, A de Reyniès, Y Allory, G Sjödahl, AG Robertson, R Seiler, ... The consensus molecular classification of muscle-invasive bladder cancer …, 2020 | 10 | 2020 |
| Molecular and clinical characterization of a claudin-low subtype of gastric cancer TF Nishijima, J Kardos, S Chai, CC Smith, DS Bortone, SR Selitsky, ... JCO Precision Oncology 1, 1-10, 2017 | 8 | 2017 |
| Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients. J Kardos, JJ Melquist, DD Chism, W Choi, K Cockerill, RK Paluri, ... Journal of Clinical Oncology 33 (7_suppl), 305-305, 2015 | 4 | 2015 |
| Muscle invasive bladder cancer: a single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BW Van Rhijn, B Winters, J Douglas, ... European Urology Supplements 3 (16), e1567-e1568, 2017 | 2 | 2017 |
| 1219 Nonclinical safety evaluation of sacituzumab govitecan, a TROP-2-directed antibody drug conjugate (ADC), for non-muscle invasive bladder cancer C McMahon, L Diehl, L Tatalick, J Boggs, S Mohanan, IK Mah, J Kardos, ... J Immunother 10 (2), A1-A1595, 2022 | 1 | 2022 |
| Clinical and molecular characterization of urothelial cancer developing after pelvic radiation. TL Rose, J Kardos, S Wobker, MI Milowsky, WY Kim Journal of Clinical Oncology 36 (6_suppl), 518-518, 2018 | 1 | 2018 |
| Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy. TL Rose, DD Chism, AS Alva, AM Deal, S Maygarden, YE Whang, ... Journal of Clinical Oncology 36 (6_suppl), 500-500, 2018 | 1 | 2018 |
| Development of subtype specific mouse models of bladder cancer CC Smith, R Saito, LM Bixby, T Utsumi, J Kardos, S Chai, SE Wobker, ... Cancer Research 77 (13_Supplement), 1654-1654, 2017 | 1 | 2017 |
| MP88-20 ESTABLISHMENT OF NOVEL MOUSE BLADDER CANCER CELL LINES MIMICKING INTRINSIC SUBTYPE OF HUMAN INVASIVE BLADDER CANCER R Saito, C Smith, J Kardos, L Bixby, S Chai, J Damrauer, T Utsumi, ... The Journal of Urology 197 (4S), e1182-e1182, 2017 | 1 | 2017 |
